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Background: Food allergy (FA) can have serious psychosocial and economic repercussions on food-allergic children
and their caregivers and be associated with negative effects on their quality of life. Food allergen immunotherapy
(IT) is a promising experimental therapy but can be linked to anxiety. This study investigated the effects of IT on
FA-specific health-related quality of life (HRQL) over a 24 month-follow-up in caregivers of children with single and
multiple food allergies. We hypothesized that characteristics such as age, asthma at baseline and respiratory allergic
reactions during therapy were key characteristics that influenced HRQL scores.
Methods: A validated Food Allergy Quality of Life – Parental Burden Questionnaire (FAQL-PB) was used to assess
HRQL. It was randomly distributed to and filled out by caregivers of 57 food-allergic children enrolled in clinical trials
of IT. The same parent answered the FABQL-PB questionnaire at baseline and for 6-month, 12- month, 18- month,
and 24-month time points on IT.
Results: Caregiver HRQL improved significantly (change < - 0.5, p <0.0001) at each follow-up time point compared
to baseline. The percentages of caregivers with improvement in HRQL progressively increased (92% at 24
month-follow-up time point compared to baseline). HRQL improved more in caregivers of participants older than
10 years or desensitized to more than 4 food allergens than those who were not (p <0.0001). Caregivers of
participants with pre-existing asthma or dose-related respiratory allergic reactions had less improvement in HRQL
than those who did not (p <0.01).
Conclusion: IT lead to improvement in caregiver HRQL. Certain characteristics were associated with greater
improvements in caregiver HRQL.
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Food allergy (FA) is an adverse immunologic response to
a dietary antigen. It is estimated that about 6% and 8%
of the pediatric population in Europe [1] and in U.S. [2],
respectively, are affected. About 1% [1] and 2.4% [2] of
European and American children, respectively, have clin-
ical reactivity to more than one food allergen. Currently,
the only FDA- and EMA- approved treatment for FA is* Correspondence: knadeau@stanford.edu
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unless otherwise stated.food allergen avoidance and rescue therapy, including
injectable epinephrine [3].
Food allergy may be associated with a negative impact
on the quality of life of patients and their families, even
more so than other chronic childhood diseases [4-6].
The burden of FA on caregivers (buying special foods,
limiting social encounters, time lost from work, chan-
ging careers and emergency room visits) has been re-
ported to play a predominant role in the total annual
economic burden of FA [7].
Food allergen immunotherapy (IT) is a promising
experimental therapy for food allergy [8] but it can be
linked to anxiety. The reported reactions during IT ared. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pothesized that baseline characteristics like age, asthma,
and respiratory allergic reactions during therapy were
key characteristics that influenced HRQL (health-related
quality of life) score.
Previously, two studies showed a HRQL improvement
with single-allergen IT after desensitization in pediatric
patients with milk (n =30) at about 12 months or peanut
allergy (n =100) at 6-9 months after therapy began
[11,12]. Our group published a study examining the ef-
fects of mIT (IT with multiple food allergens) and rush
mIT (mIT with omalizumab treatment) on caregiver
HRQL and found significant improved HRQL scores in
both groups [13]. However, in the previously published
studies there remained several unanswered questions
like whether there were sustained improvements in HRQL
scores and whether there were specific determinants of
HQRL score over the course of therapy. Therefore, we
studied a new and distinct population of participants with
a larger sample size (n = 57) and a longer follow-up of
24-months and examined characteristics associated with
worse or improved HQRL scores.Methods
Participants
Questionnaires were distributed randomly to the care-
givers of 57 children (demographic and clinical charac-
teristics of patient population are described in Table 1)
enrolled in food allergen IT between April 1 2012 and
October 1 2013. IT was performed similarly in all 57
children, as per a published protocol [9], under Stanford
IRB approval. Briefly, participants older than 4 years were
eligible for inclusion if they had proven sensitivity to one
or more food allergen documented by both a positive skin
prick test specific IgE as well as positive allergic reaction
in a double-blind placebo-controlled oral food challenge
(DBPCFC) up to a cumulative dose of 182 mg. All allergic
reactions during the course of IT were described as per
Bock’s criteria for each food allergen [14].Study intervention
The intervention used have been previously described in
detail [9]. Briefly, subjects meeting inclusion criteria were
started on a daily dose of up to 5 multiple food allergens
combined in an equivalent ratio (1:1:1:1:1) based on food
protein content. Participants underwent an initial dose es-
calation starting at 0.1 mg of total food protein up to a
maximum of 6 mg if tolerated. The maximal tolerated
dose determined daily home dose that was increased by
25% increments every other week at our research clinic
based on dose tolerability. Participants took a median of
85 weeks to reach their maintenance dose of 4000 mg
protein per food. At 24 months, participants were onmaintenance doses of their food allergen IT (4 g of each
allergen daily). No patient was treated with omalizumab.
Questionnaire
A validated Food Allergy Quality of Life – Parental Bur-
den (FAQL-PB) questionnaire was used to assess HRQL
[15]. Originally validated in the United States by Cohen
et al., it is a FA-specific HRQL questionnaire that mea-
sures parental burden related to having a child with FA.
It consists of 17 questions that are answered on a 7-
point scale and related to two main specific aspects such
as social and dietary limitation and food-related emo-
tional impact (Additional file 1: Table S1). The same
parent (12 fathers and 45 mothers) was asked to answer
the questionnaire at baseline and at 6-month, 12-month,
18-month, and 24-month time points on IT.
Statistics
Statistical analysis was performed using t test with Welch’s
correction and the Mann-Whitney test for unpaired vari-
ables and Wilcoxon for paired variables, as appropriate. All
tests were two-tailed and significance was set at p-value
less than 0.05.
The MID (minimal clinically important difference) was
used to assess the clinical relevance. Defined as the smal-
lest change in HRQL score that participants perceive as
clinically important, it has been estimated to be approxi-
mately 0.5 for scores graded on a 7-point scale in several
HRQL questionnaires, including questionnaires determin-
ing parental quality of life [16-20].
All statistical analyses and graphing were carried out
using GraphPad Prism software (GraphPad Software,
San Diego, CA).
Results
All randomly chosen 57 caregivers filled out the question-
naire for baseline and at least one follow-up time-point.
Particularly, 57 answered for 6-month follow-up time-
point and baseline, 45 for 12-month follow-up time-point
and baseline, 41 for 18-month follow-up time-point
and baseline, and 37 for 24-month follow-up time-
point and baseline (Table 1). 37 caregivers completed
all 5 time-points.
The HRQL scores improved significantly (change < -
0.5, p <0.0001) between each time point and baseline. The
percentages of caregivers documenting improvements in
HRQL scores of their children between 24-month and
baseline were progressively higher over time (42%, 71%,
76% and 92% respectively at the 6-month, 12-month, 18-
month and 24-month follow-up time point compared to
baseline). The percentage of those whose HRQL score
deteriorated (change > +0.5) were 0%, 0%, 2%, and 3%
respectively at the 6-month, 12-month, 18-month and
24-month follow-up time point compared to baseline









Number of subjects 57 57 45 41 37
Median Age in years (range) 9 (4 – 18) 9 (4 – 18) 9 (4 – 18) 9 (4 - 18) 9 (4 – 18)
Male 35 (61%) 35 (61%) 25 (56%) 24 (58%) 22 (59%)
Ethnicity
Caucasian 30 (53%) 30 (53%) 25 (55%) 23 (56%) 20 (54%)
Asian 18 (32%) 17 (32%) 13 (29%) 11 (27%) 11 (30%)
Indian 5 (9%) 5 (9%) 5 (11%) 5 (12%) 5 (13%)
Hispanic 3 (5%) 3 (5%) 2 (4%) 2 (5%) 1 (3%)
African-American 1 (2%) 1 (2%) 0 (0%) 0 (0%) 0 (0%)
Coexisting atopic disease
Asthma 37 (65%) 37 (65%) 27 (60%) 37 (59%) 21 (57%)
Allergic Rhinitis 30 (52%) 30 (52%) 25 (55%) 20 (50%) 20 (54%)
Atopic Dermatitis 17 (30%) 17 (30%) 13 (30%) 12 (30%) 12 (32%)
Number of allergens
1 24 (42%) 24 (42%) 14 (31%) 13 (32%) 14 (38%)
2 13 (23%) 13 (23%) 13 (29%) 11 (27%) 8 (22%)
3 8 (14%) 8 (14%) 8 (18%) 8 (19%) 8 (22%)
4 4 (7%) 4 (7%) 3 (6%) 3 (7%) 2 (5%)
5 8 (14%) 8 (14%) 6 (13%) 5 (12%) 5 (13%)
Allergens
Peanut 48 (84%) 47 (84%) 38 (84%) 33 (80%) 31 (84%)
Cashew 17 (30%) 17 (30%) 15 (33%) 13 (32%) 17 (46%)
Walnut 12 (21%) 12 (21%) 11 (24%) 10 (24%) 9 (24%)
Egg 12 (21%) 12 (21%) 10 (22%) 11 (27%) 8 (22%)
Pecan 10 (17%) 10 (17%) 9 (20%) 8 (19%) 8 (22%)
Milk 8 (14%) 8 (14%) 7 (15%) 7 (17%) 6 (16%)
Almond 6 (10%) 6 (10%) 5 (11%) 5 (12%) 5 (13%)
Sesame 4 (7%) 4 (7%) 4 (9%) 4 (10%) 4 (11%)
Hazelnut 3 (5%) 3 (5%) 3 (7%) 2 (5%) 1 (3%)
Shellfish 3 (5%) 3 (5%) 1 (2%) 1 (2%) 1 (3%)
Demographics and clinical characteristics of patients are shown at baseline, 6-month follow-up, 12-month follow-up, 18-month follow-up, and 24-month follow-up
time point.
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remained unchanged (change between -0.5 and 0.5)
were 58%, 29%, 22% and 5%, respectively at the 6-month,
12-month, 18-month and 24-month follow-up time point
compared to baseline (Figure 1).
We then examined the effect of baseline characteris-
tics on the degree of HRQL improvement on IT at
24 months. Baseline demographic characteristics of the
study participants are shown in Table 1. To determine if
changes in the HRQL score were associated with age,
we divided 35 subjects into two groups: age <10 years
(n =22) and age ≥10 years (n =15). Caregivers of patients
in the ≥10 years age group had significantly moreimprovement compared to those in the <10 years age
group (p <0.0001) (Figure 2A). Within the FAQL-PB ques-
tionnaire of 17 questions, the questions related to choice of
restaurant (p <0.0001), planning to participate in social ac-
tivities with others involving food on one side (p <0.001),
and about anxiety relating to food allergy (p <0.001) were
the most significantly different for ages greater than or
equal to 10 years (Figure 2A). There was no association be-
tween the gender of the participants and the change in
HRQL score (Additional file 2: Figure S1A).
Next, we investigated the role of co-morbid allergic
disorders at baseline. HRQL scores of participants with-
out asthma (n =21) had significantly more improvement
Figure 1 Percentages of participants with deterioration, no change, or improvement in the HRQL score. Percentages of participants
whose HRQL score deteriorated (change >0.5), remained unchanged (change between -0.5 and 0.5), or improved (change < -0.5) at (A) 6-month
follow-up, (B) 12-month follow-up, (C) 18-month follow-up, and (D) 24-month follow-up from baseline. ****p <0.0001.
Arasi et al. Allergy, Asthma & Clinical Immunology 2014, 10:57 Page 4 of 7
http://www.aacijournal.com/content/10/1/57(p <0.01) when compared to participants with baseline
asthma (n =16). This difference was detected most sig-
nificantly in the questions related to the choice of res-
taurant (p <0.001), the risk of not overcoming food
allergy (p <0.01), and the burden for the child because of
their own food allergy (p <0.01) (Figure 2B). Baseline co-
morbid allergic rhinitis (Figure 2C) and atopic dermatitis
(Figure 2D) did not significantly affect changes in HRQL
score.
We hypothesized that certain allergic events during IT,
like wheezing, would affect the outcome of HRQL score.
We found that dose-related respiratory allergic reactions
(wheezing and cough) were associated (p <0.0001) with
less improvement in the HRQL score. Questions related
to the trouble of overcoming food allergy (p <0.0001)
and worry of not being able to help their own child in case
of allergic reaction to food (p <0.001) and dietary-social
limitations (planning holiday/vacation, choicing a restaur-
ant, participating in social activities with others involving
food, p <0.001) were the most significantly different for
dosing-related respiratory allergic reactions (Figure 2E).
All subjects with respiratory allergic reactions during
dosing were asthmatic at baseline. No association was de-
tected with dosing-related abdominal pain and vomiting
(Figure 2F), allergic rhinitis (Additional file 2: Figure S1B),
or skin reactions (Additional file 2: Figure S1C).
We also analyzed if changes in HRQL score varied
based on number or type of food allergens used during
desensitization. We found that improvement in HRQL
scores of subjects treated with 4-5 food allergens (n =6)
were significantly greater compared to those treated with
1-3 foods (p <0.0001). This difference were detected most
significantly in the questions related to sadness regarding
the child’s burden related to food allergy (p <0.0001), plan-
ning holiday/vacation (p <0.0001) and choice of a restaur-
ant (p <0.0001), as shown in Figure 2G. There were nosignificant differences in the changes of HRQL score be-
tween subjects treated with a single food allergen (n =14)
versus multiple food allergens (n =23), (Additional file 2:
Figure S1D), and between subjects treated with one or
two food allergens (n =15) versus more than two food al-
lergens (n =22), (Additional file 2: Figure S1E).
Caregivers’ HRQL scores of 6 subjects treated with cow’s
milk had a significantly greater improvement (p =0.006)
than subjects treated with other food allergens (n =31).
This improvement was detected most significantly in
the questions regarding the concern about child’s nutri-
tion (p <0.001), and the need to spend extra time pre-
paring meals (i.e., label reading, extra time shopping,
preparing meals, etc.) (p <0.001) and to take special pre-
cautions before going out of the home with their child
(p <0.001), (Figure 2H). Significant differences were not
found in HRQL score change between the presence (n =17)
or absence (n =20) of cashew in the food allergens used in
treatment (Figure 2I).
Discussion
Using a quality of life questionnaire specifically validated
for food allergy, we examined the effects of IT on the
quality of life of caregivers of patients suffering from single
and multiple food allergies. In addition to following these
participants for 24 months (longer than any previously
published study to our knowledge), we have determined
characteristics that could possibly assist in identifying
those who may psychologically benefit the most from IT.
The improvement we saw in HRQL scores on IT is con-
sistent with previously published data [13,18,19]. Recently,
the relevance of IT as a long-term intervention for food
allergy has come into question, as studies have shown
limited rates of sustained unresponsiveness with IT [21].
This study, consistent with our previously published study











c) Number and type of food allergens:
b) Adverse effects of therapy:
Figure 2 Changes in individual FAQL-PB question scores at 24-month follow-up time point from baseline for: a) baseline characteristics:
(A) age, (B) asthma at baseline, (C) allergic rhinitis at baselineand (D) atopic dermatitis at baseline; b) adverse effects of therapy:
(E) respiratory-related allergic reactions and (F) dosing- related abdominal pain and/or vomiting; c) number and type of food
allergens: (G) 1-3 versus 4-5 foods; (H) milk; (I) cashew. Changes in individual FAQL-PB question scores are shown between caregivers of:
(A) patients <10 years old and patients ≥10 years old; (B) patients with asthma and patients without asthma at baseline; (C) patients with allergic
rhinitis and patients without allergic rhinitis at baseline; (D) patients with atopic dermatitis and without atopic dermatitis at baseline; (E) patients with
at least one documented by a physician dosing- related respiratory adverse reaction (wheezing and/or cough) and patients without those; (F) patients
with abdominal pain and/or vomiting and patients without abdominal pain and/or vomiting; (G) patients in treatment with 1-3 food allergens and
patients in treatment with 4-5 food allergens; (H) patients in treatment with milk and patients not in treatment with milk; (I) patients in treatment with
cashew and patients not in treatment with cashew. *p <0.05, **p <0.01, ***p <0.001, ****p <0.0001. Bars without asterisks represent
non-significant changes.
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Long-term follow-up is critical to test net improvements
over time. We plan to continue to follow these caregivers
and participants to allow future studies on HRQL.
The significantly greater improvement in caregiver
HRQL in patients older than 10 years raises the interest-
ing question of how to possibly prioritize some age groups
for IT. This question needs to be studied long term by
utilizing validated food allergy quality-of-life question-
naires for different age groups (FAQL-teen, FAQLQ-adult,
etc) to assess the effect of IT on participants themselves.
We also found less improvement in caregiver HRQL
in subjects with baseline asthma. Clearly food-induced re-
spiratory symptoms should be managed differently from
asthma exacerbations triggered by other common triggers,
with injectable epinephrine as the treatment of choice as
opposed to inhaled beta-agonists. Recent studies demon-
strate not only that food allergy and asthma often coexist
but also that having these co-morbid conditions worses
prognosis: children with food allergies and asthma are
more likely to have near-fatal or fatal allergic reactions to
food (among which respiratory symptoms) and more
likely to have severe asthma [22] with negative impact on
quality of life. This may explain why these patients in
particular were precluded from greater improvements in
HRQL [23], as we found that caregivers of patients with
dose-related respiratory allergic reactions had less im-
provement in HRQL. All patients with dose-related re-
spiratory allergic reactions were asthmatic at baseline. As
respiratory allergic events are more tied to life-threatening
events, they may be particularly burdensome [24], increas-
ing parents’ sense of anxiety about future reactions.
Compared to patients with single food allergies, pa-
tients with multiple food allergies experience a greater
decrease in quality of life [15,23], are more likely to suf-
fer from dietary deficiencies [25] and are less prone to
spontaneously outgrow their food allergies [26]. Building
on our previous study [13], which found that mIT im-
proves caregiver HRQL in children with multiple food
allergies, we analyzed a larger study population in this
study and found that HRQL score improves more in sub-
jects treated with 4-5 food allergens compared to those
treated with <4 food allergens (p <0.0001) (Figure 2G). As
a similar difference was not seen between single versus
multiple food allergen therapy (Additional file 2: Figure
S1D), and <2 versus ≥2 food allergen therapy (Additional
file 2: Figure S1E), it is possible that patients with multiple
food allergies must be treated with at least a certain num-
ber of food allergens to achieve a greater improvement in
caregiver HRQL.
There are limitations to our study. Although our sam-
ple size was larger than our previous study, it still lacked
power to detect significant differences between some types
of food allergens and between quality of allergic reactions(severe, moderate vs. mild). There was no untreated con-
trol group. However, our hypothesis was best tested by
comparisons against baseline to allow for each caregiver’s
scoring and perception to be similarly tested.
In conclusion, the results reported here support our
previous findings [13] that IT could possibly lead to sig-
nificant and long-term improvements in caregiver HRQL.
Furthermore, we were able to identify baseline character-
istics that could potentially help identify patients who
would benefit the most from IT. Validated measures of
quality of life should be included in future food allergy
clinical trials.
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